Cart (0 items)
|
Home >> Executive Summary |
|
|
Executive Summary |
|
CH3 BioSystems is a biotechnology company built upon an entirely new patent-protected chemical technology
to identify and commercialize drug and diagnostic candidates. The first sales of novel molecular tools to
facilitate biomedical research began in JULY of 2008. CH3 BioSystems is the only biotechnology company
focused on protein methylation biology to understand better many of the diseases that affect millions
of people around the world.
Scientists are discovering that protein methylation is significantly involved in normal and pathological cellular physiology. The detection, identification and characterization of methylproteins will contribute to a better understanding of how deadly diseases develop. Methylprotein “biomarkers” are expected to help usher in the new era of personalized medicine. CH3 BioSystems LLC is uniquely positioned to take advantage of the long-term projected expansions in the antibody, biomarker and proteomics segments of the biotechnology market. CH3 BioSystems products are based on the development of protein methylation technology. Through basic research discovery partnerships with academia and industry, CH3 BioSystems is expanding the reach of protein methylation biology to include proteomics, diagnostic devices and ultimately pharmaceutical agents. Our vision is to promote the growth of the field of protein methylation biology and to provide the cutting edge clinically relevant products of the 21st century. Our vision is to promote the growth of the field of protein methylation biology and to provide the cutting edge clinically relevant products of the 21st century. Please indicate your interest as a potential investor and contact us for more information. |
|
